These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

962 related articles for article (PubMed ID: 29676846)

  • 41. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Ahmed H; Elgebaly A; Abushouk AI; Hammad AM; Attia A; Negida A
    Antivir Ther; 2017; 22(5):369-379. PubMed ID: 27588749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    El-Nahaas SM; Fouad R; Elsharkawy A; Khairy M; Elhossary W; Anwar I; Abdellatif Z; Maher RM; Bekheet N; Esmat G
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1194-1199. PubMed ID: 30096091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Wiegand J; Buggisch P; Mauss S; Boeker KHW; Klinker H; Müller T; Günther R; Serfert Y; Manns MP; Zeuzem S; Berg T; Hinrichsen H; C-Registry GH
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1424-1431. PubMed ID: 31589184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    Townshend-Bulson L; Roik E; Barbour Y; Bruden DJT; Homan CE; Espera HGF; Stevenson TJ; Hewitt AM; Rhodes W; Gove JE; Plotnik JN; Snowball MM; McGilvray J; Simons BC; Johnston JM; McMahon BJ
    PLoS One; 2021; 16(12):e0260970. PubMed ID: 34855920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder.
    Trabut JB; Barrault C; Charlot H; Carmona D; Bourdel A; Benslimane M; François M; Kini-Matondo W; Causse R; Roudot-Thoraval F; Hézode C
    J Addict Med; 2018; 12(5):346-352. PubMed ID: 29702515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
    Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Soñora M; Cristina J; Moratorio G; Hernández N; Moreno P
    BMC Infect Dis; 2021 Apr; 21(1):387. PubMed ID: 33902462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
    Osinusi A; Kohli A; Marti MM; Nelson A; Zhang X; Meissner EG; Silk R; Townsend K; Pang PS; Subramanian GM; McHutchison JG; Fauci AS; Masur H; Kottilil S
    Ann Intern Med; 2014 Nov; 161(9):634-8. PubMed ID: 25364884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tsuji K; Kurosaki M; Itakura J; Mori N; Takaki S; Hasebe C; Akahane T; Joko K; Yagisawa H; Takezawa J; Nakata R; Kusakabe A; Kojima Y; Kimura H; Tamada T; Kobashi H; Mitsuda A; Kondou M; Ogawa C; Uchida Y; Sohda T; Narita R; Izumi N
    J Gastroenterol; 2018 Oct; 53(10):1142-1150. PubMed ID: 29626296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    He QF; Zhang QF; Zhang DZ
    Dig Dis Sci; 2016 Nov; 61(11):3108-3117. PubMed ID: 27619394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS.
    Debnath P; Chandnani S; Rathi P; Nair S; Pawar V; Contractor Q
    Arq Gastroenterol; 2020; 57(1):39-44. PubMed ID: 32294734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.